Frankfurt - Delayed Quote EUR

BioCryst Pharmaceuticals, Inc. (BO1.F)

Compare
8.39
-0.49
(-5.47%)
As of 1:08:53 PM GMT+1. Market Open.

Research Analysis

Revenue vs. Earnings

Revenue 117.08M
Earnings -14.03M

Q4'23

Q1'24

Q2'24

Q3'24

-50M
0
50M
100M
 

Analyst Price Targets

Earnings Estimate

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
No. of Analysts --------
Avg. Estimate 0000
Low Estimate 0000
High Estimate 0000
Year Ago EPS --------

Revenue Estimate

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
No. of Analysts 4649
Avg. Estimate 131.1M126.64M450.36M548.9M
Low Estimate 130.8M121.67M449.98M538M
High Estimate 131.77M132.06M450.94M557.68M
Year Ago Sales 93.4M92.76M331.41M450.36M
Sales Growth (year/est) 40.36%36.52%35.89%21.88%

EPS Trend

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
Current Estimate 0000
7 Days Ago 0000
30 Days Ago 0000
60 Days Ago 0000
90 Days Ago 0000

EPS Revisions

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
Up Last 7 Days --------
Up Last 30 Days --------
Down Last 7 Days --------
Down Last 30 Days --------

Growth Estimates

Current Qtr.Next Qtr.Current YearNext Year
BO1.F --------
S&P 500 13.78%8.04%13.14%14.09%

Upgrades & Downgrades

Reiterates JMP Securities: Market Outperform to Market Outperform 1/31/2025
Maintains Evercore ISI Group: Outperform to Outperform 1/13/2025
Maintains Needham: Buy to Buy 1/13/2025
Maintains Needham: Buy to Buy 12/17/2024
Reiterates RBC Capital: Outperform to Outperform 11/5/2024
Reiterates Needham: Buy to Buy 11/5/2024